Key takeaways
- • Trial: SCALE Obesity and Prediabetes (NCT01272219) — Phase 3, 3,731 participants over 56 weeks.
- • Drug studied: Saxenda (Liraglutide) — FDA-approved branded product.
- • Primary endpoint: Percent change in body weight from baseline to week 56 in adults with obesity or overweight with comorbidities
- • Key result: Mean weight loss 8.0% on liraglutide 3.0mg vs 2.6% on placebo
- • Published: New England Journal of Medicine, 2015.
Study design
SCALE Obesity and Prediabetes was a phase 3 randomized controlled trial enrolling 3,731 participants over 56 weeks. The trial studied Saxenda (Liraglutide) for obesity / overweight and was published in New England Journal of Medicine in 2015.
Primary endpoint
Percent change in body weight from baseline to week 56 in adults with obesity or overweight with comorbidities
Key results
| Measure | Value |
|---|---|
| Headline result | Mean weight loss 8.0% on liraglutide 3.0mg vs 2.6% on placebo |
| Mean weight loss (highest dose arm) | 8.0% |
| Participants | 3,731 |
| Duration | 56 weeks |
| Phase | Phase 3 |
Citation
SCALE Obesity and Prediabetes. Published in New England Journal of Medicine, 2015.
GLP1Zoom did not conduct this trial. We summarize published primary literature. For verbatim methods and full results, consult the primary publication and the ClinicalTrials.gov registry record.
Related
- Saxenda drug page — pricing, FDA status, side effects, alternatives
- All liraglutide trials
- GLP-1 clinical trials database
Other Saxenda trials
- SCALE Maintenance — Additional 6
Important: This trial was conducted on the FDA-approved branded product Saxenda. Compounded versions of Liraglutide have NOT been studied in equivalent randomized controlled trials, and their efficacy and safety profile may differ.
GLP1Zoom is an affiliate-only comparator. We cite published trials; we do not conduct them. This page is informational and is not a substitute for personalized medical advice — always confirm any treatment decision with your prescribing clinician. Full disclaimer.